MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results